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Hypoxia is an important microenvironmental factor that induces cancer metastasis. Hypoxia/hypoxia-inducible
factor-1α (HIF-1α) regulates many important steps of the metastatic processes, especially epithelial-mesenchymal
transition (EMT) that is one of the crucial mechanisms to cause early stage of tumor metastasis. To have a better
understanding of the mechanism of hypoxia-regulated metastasis, various hypoxia/HIF-1α-regulated target genes
are categorized into different classes including transcription factors, histone modifiers, enzymes, receptors, kinases,
small GTPases, transporters, adhesion molecules, surface molecules, membrane proteins, and microRNAs. Different
roles of these target genes are described with regards to their relationship to hypoxia-induced metastasis. We hope
that this review will provide a framework for further exploration of hypoxia/HIF-1α-regulated target genes and a
comprehensive view of the metastatic picture induced by hypoxia.
Keywords: Hypoxia, Hypoxia-inducible factor, Target genes, Metastasis, Epithelial-mesenchymal transitionReview
Introduction
Hypoxia is a critical microenvironmental factor that is
demonstrated to induce tumor metastasis [1-5]. Hypoxia
has profound effects in metabolism, angiogenesis, innate
immunity, and stemness induction [1]. The effects of
hypoxia are usually mediated by hypoxia-inducible fac-
tors (HIFs), i.e. HIF-1α and HIF-2α [1−4]. HIFs heterodi-
merize with a common partner, HIF-1β (or aryl
hydrocarbon receptor nuclear translocator (ARNT)), to
regulate downstream target gene expression through a
hypoxia-response element (HRE) [1]. The consensus of
HRE is 5’-RCGTG-3’, although other sequences were
shown to respond to HIFs [3,4]. An ancillary sequence
was shown to couple with the canonical HRE to better
respond to the binding of HIFs [6]. Although microarray
and genomics approaches were performed to identify
various downstream targets of HIFs, these targets only
represent a small subset of targets reported in the litera-
ture [7-10]. More than one thousand target genes were
reported to be regulated by HIFs to mediate the effects* Correspondence: kjwu2@ym.edu.tw
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reproduction in any medium, provided the orinduced by hypoxia [3,4]. Although most target genes
were identified through their regulation by HIF-1α, other
targets could be solely regulated by HIF-2α [11]. How-
ever, most targets are usually regulated by both HIF-1α
and HIF-2α [11]. Opposing activities between HIF-1α
and HIF-2α could occur [11]. Cancer metastasis is
the most significant etiology to cause patient death of
cancer patients [12]. Different steps are proposed for a
tumor cell to become metastatic including epithelial-
mesenchymal transition (EMT), extracellular matrix
modulation, intravasation, circulation, extravasation,
homing and the premetastatic niche, and organotropic
colonization [5,12]. Due to the causal role of hypoxia in
the induction of metastasis [1-5], it will be important to
assign the role of these hypoxia-regulated targets accord-
ing to the various steps of metastasis. In this review, we
will focus on the hypoxia/HIF-1α-regulated target genes
that are shown to modulate tumor migration, invasion,
and metastatic property. These target genes are divided
into various categories including transcription fac-
tors, chromatin modifiers, enzymes, receptors, small
GTPases, transporters, adhesion molecules, surface
molecules, membrane proteins, and microRNAs. We
hope that this review will provide a framework of
hypoxia-regulated targets and further elucidate theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hypoxic condition.
Transcription factor and histone modifiers
One well-studied aspect of hypoxia-induced metastasis
is that hypoxia induces various transcriptional regulators
(also called EMT regulators) to cause EMT [13-16]. The
EMT regulators including Twist1, Snail, Slug, ZEB1,
ZEB2, and E12/E47 have been shown to be either dir-
ectly or indirectly regulated by HIF-1α [17]. These EMT
regulators subsequently bind to the promoters of EMT
marker genes including E-cadherin, vimentin, and N-
cadherin to mediate EMT [16,17]. The EMT regulator
Snail is a good example of indirect regulation by hypoxia
through the lysyl oxidase-like 2 enzyme [18]. The nu-
clear localization of Snail could also be regulated by ERβ
(estrogen receptor β) to impede EMT in prostate cancer
cells [19]. Other transcription factors are also regulated
by HIF-1α to contribute to metastasis. For example, in-
hibitor of differentiation/DNA binding 2 (ID2) is
regulated by HIF-1α to cause dedifferentiation of neuro-
blastoma cells, which leads to less mature and more
aggressive tumors [20]. Hypoxia upregulates the expres-
sion of Ewing Sarcoma-Friend leukemia virus integration
1 (EWS-FLI1) chimeric protein to modulate its tran-
scriptional signature and increase the malignant proper-
ties of Ewing’s sarcoma cells [21]. Hypoxia activates
β-catenin in hepatocellular carcinoma cells to induce
EMT and enhance their metastatic potential [22]. Inverse
correlation between the expression of caudal type
homeobox 2 (CDX2), a homeodomain protein, and HIF-
1α is observed in colorectal cancer samples [23]. Finally,
hypoxia converts the inhibitor function of SMAD family
member 7 (SMAD7, an inhibitor of the TGF-β signaling
pathway) into a promoter of cell invasion [24]. In
addition to transcriptional factors, chromatin modifiers
could also be regulated by hypoxia. Induction of histone
lysine-specific demethylase 4B (KDM4B, JMJD2B) corre-
lates with invasion and advanced clinical stage in colo-
rectal cancers [25]. JMJD2B also plays a central role in
gastric cancer cell growth [26]. JMJD2C (KDM4C) is
induced by HIF-1α to mediate epigenetic regulation of
HIF-1α downstream genes involved in metabolic repro-
gramming and lung metastasis of breast cancer [27].
The histone methyltransferase mixed lineage leukemia 1
(MLL1) is induced by hypoxia to enhance hypoxic re-
sponse [28]. All these results demonstrated that hyp-
oxia/HIF-1α regulates both transcription factors and
chromatin modifiers to induce metastasis in an EMT-
dependent or independent manner.
Enzymes that are regulated by hypoxia/HIF-1α
Hypoxia/HIF-1α is originally shown to regulate the
expression of metalloproteases including matrixmetalloprotease-1 (MMP1) and MMP3 to induce metas-
tasis [29]. In contrast, HIF-2α activates the expression
of membrane type-1 matrix metalloproteinase (MT1-
MMP) in von Hippel-Lindau renal cell carcinoma
[29,30]. The most significant enzyme that is regulated by
hypoxia to cause metastasis is lysyl oxidase (LOX) [31].
Secreted LOX is required for adhesion interactions ne-
cessary for migration through focal adhesion kinase ac-
tivity and cell to matrix adhesion [31]. Lysyl oxidase is
also a crucial mediator of bone marrow cell recruitment
to form the premetastatic niche through crosslinking
collagen IV and recruiting CD11b myeloid cells [32].
Other lysyl oxidase-like enzymes that are regulated by
HIF-1α also play an important role in the formation of
breast cancer metastatic niche [33]. Loss of programmed
cell death 4 (Pdcd4), a tumor suppressor, increases the
expression of lysyl oxidase and hypoxia-induced breast
cancer cell invasion through a HIF-1-independent mech-
anism [34]. A disintegrin and metalloproteinase with
thrombospondin motifs 1 (ADAMTS1) is a hypoxic
early response gene in endothelial cells that promotes
migration under hypoxia [35]. Hypoxia activates the ex-
pression of angiotensin converting enzyme (ACE) and
inhibits ACE2 expression in human pulmonary smooth
muscle cells [36]. Sulfatase 1 (Hsulf-1) modulates the
sulfation state of heparin sulfate proteoglycans and hyp-
oxia represses Hsulf-1 expression that leads to increased
bFGF signaling and the promotion of migration and in-
vasion of breast cancer cells [37]. Hypoxia promotes iso-
citrate dehydrogenase (IDH2)-dependent carboxylation
of α-ketoglutarate to support cell growth and viability
[38]. HIF-1α regulates xeroderma pigmentosum, com-
plementation group A (XPA) expression and contributed
to cisplatin resistance in lung cancer [39]. The results
described above indicate that various enzymes are regu-
lated by hypoxia/HIF-1α to regulate the metastatic activ-
ity of tumor cells.
Receptors, kinases, small GTPases, and transporters
Various receptors, receptor-activated kinases, small
GTPases, and transporters are regulated by hypoxia/
HIF-1α to play a significant role in cancer metastasis.
For example, chemokine receptor 4 (CXCR4) is one of
the early identified hypoxia/HIF-1α target genes that
mediates hypoxia-induced angiogenesis and metastasis
[40]. Similar regulation of another chemokine receptor,
chemokine (C-X3-C motif ) receptor 1 (CX3CR1), is also
shown in prostate cancer and pancreatic ductal adeno-
carcinoma cells to mediate their migration and invasion
[41,42]. Notch signaling has recently been shown to be
required for hypoxia-induced EMT, tumor cell migration
and invasion through activation of Snail [43]. The
urokinase-type plasminogen activator receptor (uPAR) is
activated by HIF-1α and is crucial for hypoxia-induced
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inhibitor-1 (PAI-1), a factor related to the uPAR system
that predicts poor prognosis in many cancers, is regu-
lated by hypoxia through the cooperative functions of
HIF-1α, Egr-1, and C/EBPα [45]. The 67-kDa laminin re-
ceptor was shown to be activated by hypoxia to promote
gastric cancer metastasis through increasing uPA and
MMP9 expession [46]. Toll-like receptor 4 (TLR4) is
induced by HIF-1α to promote pancreatic tumor cell
growth [47]. C-Met protooncogene expression is regu-
lated by hypoxia to enhance scatter factor/hepatocyte
growth factor (SF/HGF)-induced cell migration and in-
vasion in glioma and trophoblast cells [48,49]. Pericyte
depletion triggers hypoxia-induced EMT and metastasis
through the c-Met signaling [50]. RON tyrosine kinase is
a direct target of HIF-1α and mediates invasion of breast
carcinoma cells [51]. Nitric oxide-induced macrophage
migration is mediated through HIF-1α-regulated small
GTPases Cdc42 and Rac1 [52]. RhoE activation by HIF-
1α mediates hypoxia-induced EMT of gastric cancer
cells [53]. Insulin receptor substrate 2 (IRS-2) is regu-
lated by hypoxia to promote breast carcinoma cell sur-
vival and invasion [54]. Different transporters including
glucose transporter type 1 (glut-1) and multidrug resist-
ance protein 1 (MDR1) are regulated by hypoxia/HIF-1α
and implicated in the metastatic processes [55,56]. A
truncated form of the voltage-dependent anion channel
1 (VDAC1) is induced by HIF-1α to promote cancer cell
survival and correlates with chemotherapy resistance in
lung cancer patients [57].
Adhesion molecules, surface molecules, membrane
proteins, and various proteins implicated in
hypoxia-induced metastasis
Various adhesion or surface molecules, membrane
proteins, and miscellaneous proteins are regulated
by hypoxia/HIF-1α and involved in hypoxia-induced
metastasis. For breast cancer, angiopoietin-like 4
(ANGPTL4) and L1 cell adhesion molecule (L1CAM)
are the two important molecules that mediate vascular
metastasis of hypoxic breast cancer cells to the lungs
[58]. ANGPTL4 inhibits EC (endothelial cell)-EC inter-
actions, whereas L1CAM promotes the adherence of
breast cancer cells to ECs [58]. HIF-1α mediates anoikis
resistance through suppression of α5 integrin [59].
CD151, a member of the tetraspanin family that plays a
role in cell adhesion and motility, is repressed by hyp-
oxia to regulate the detachment of colorectal cancer cells
from the primary site and homing in the second site
[60]. CD24, a cancer stem cell-associated membrane
protein, is an effector of HIF-1α-driven primary tumor
growth and metastasis [61]. CD147 is induced by HIF-
1α and Sp1 to promote glycolysis and tumor progression
in epithelial solid tumors [62]. Galectin-1, one of theimportant lectins contributing to malignant tumor
formation, is induced by HIF-1α to mediate migration
and invasion of colorectal cancer cells [63]. MUC1, an
O-glycoprotein membrane-bound mucin, is a HIF-1α tar-
get that plays a role in regulating the migration and inva-
sive property of renal cell carcinoma cells [64]. Semaphorin
4D is induced by HIF-1α to promote angiogenesis and
enhance tumor invasive growth of head and neck can-
cers [65]. Caveolin-1, an essential structural constituent
of caveolae on the cell membrane involved in endocyto-
sis, is upregulated by HIF-1α to promote ligand-
independent EGF receptor signaling and increase the
cell proliferative, migratory, and invasive capacities [66].
Human enhancer of filamentation 1 (HEF1, NEDD9,
Cas-L), a scaffold protein implicated in cellular attach-
ment and motility, is a mediator of HIF-1α-induced mi-
gration in colorectal carcinoma cells [67]. Liprin-α4 is a
HIF-1α-regulated cytoplasmic protein required for main-
tenance of cell-cell contacts in renal cell carcinoma [68].
Two matricellular proteins CYR61 (CCN1) and NOV
(CCN3) are regulated by HIF-1α and TGF-β3 in human
trophoblasts and increase their migration and invasion
[69]. Prostate specific antigen (PSA), one of the andro-
gen receptor target genes involved in tumor invasion, is
induced by HIF-1α in prostate cancers [70]. Finally, pro-
teomics experiments identify two HIF-1-inducible tar-
gets (S100A4, CapG) and S100A4 is involved in
migration and invasion of cancer cells [71]. It is obvious
that various types of proteins can play a significant role
in mediating hypoxia-induced migration and invasive
property of cancer cells.
microRNA targets
Various microRNAs are shown to be regulated by hyp-
oxia/HIF-1α. A recent review describing the various
microRNAs regulated by hypoxia provides a concise
summary of the roles of these microRNAs in metabol-
ism, DNA damage response, and angiogenesis [72].
However, the role of these microRNAs in metastasis was
not elucidated in this review. Among the microRNAs
regulated by hypoxia, miR-210 is the critical microRNA
implicated in tumor initiation and metastatic potential
by targeting different downstream molecules including
genes expressed under normoxia and vacuole membrane
protein 1 (VMP1) [73,74]. MiR-210 is proposed to be a
micromanager of the hypoxia pathway [75]. Reversion-
inducing-cysteine-rich protein with kazal motifs (RECK)
is regulated by both hypoxia and Ras-signaling pathways
through three groups of microRNAs (miR-15b/16, miR-
21, and miR-372/373) [76]. Hypoxia represses miR-34a
that targets the Notch signaling pathway and promotes
EMT in tubular epithelial cells [77]. HIF-α downregu-
lates miR-17/20a that targets p21 and signal transducer
and activator of transcription 3 (STAT3) and inhibited
Table 1 Classification of the hypoxia-regulated genes
Biological function Gene symbol/ alias References
Transcription factors Twist1, Snail, Slug, ZEB1, ZEB2, E12/E47, ID2,EWS-FLI1, β-catenin, CDX2, SMAD7 [13-16,20-24]
Histone modifiers JMJD2B, JMJD2C, MLL1 [25-28]
Enzymes MMP1, MMP3, MT1-MMP, LOX, ADAMTS1, ACE, ACE2, Hsulf-1, IDH2, XPA [29-33,35-39]
Receptors, receptor-associated kinase CXCR4, CX3CR1, Notch, uPAR, PAI-1, 67-kDa laminin receptor, TLR4, c-Met,
RON tyrosine kinase
[40-51]
small GTPases, intracellular signaling molecules Cdc42, Rac1, RhoE, IRS-2 [52-54]
Transporters glut-1, MDR1, VDAC1 [55-57]
Membrane proteins ANGPTL4, L1CAM, α5 integrin, CD151, CD24, CD147, Galectin-1, MUC1,
Semaphorin 4D, Caveolin-1
[58-66]
Scaffold protein, cytoplasmic protein HEF1, Liprin-α4 [67,68]
Matricellular proteins CYR61, NOV [69]
microRNAs miR-210, miR-15b/16, miR-21, miR-372/373, miR-34a, miR-17/20a, miR-103/107,
miR-126
[73-80]
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miR-103/107 targets the tumor suppressors death-
associated protein kinase (DAPK) and Kruppel-like fac-
tor 4 (KLF4) to promote metastasis of colorectal cancer
[79]. MiR-107 is also induced by p53 to repress the ex-
pression of HIF-1β and suppress tumor growth and
angiogenesis [80]. Recent deep sequencing experiments
to search for microRNAs regulated by hypoxia resulted
in the discovery of known and novel microRNAs [81].
MiR-210 is still the prominent microRNA that was iden-
tified under hypoxia together with other known micro-
RNAs (e.g. miR-126) and novel microRNAs. The role of
these newly discovered microRNAs in metastasis
remains to be determined.
Conclusions
Hypoxia is one of the most important environmental
factors that induce cancer metastasis. Hypoxia-regulated
biological effects have been extensively investigated. It is
obvious that hypoxia regulates key steps of the meta-
static process. Through outlining various targets regu-
lated by hypoxia/HIF-1α to mediate tumor metastasis,
the review wishes to provide a comprehensive guide
according to the various categories described. A sum-
mary of all these targets is listed in Table 1. Although
angiogenesis is regulated by hypoxia and can contribute
to tumor metastasis [1,2], the review only focuses on the
targets related to the various steps controlling metastasis
[5]. In addition, various targets regulated by hypoxia/
HIF-1α to mediate other biological effects such as
metabolism may also contribute to metastasis [1,2].
The functions mediated by these targets related to
metabolism need to be verified using the in vitro and
in vivo metastatic assays to demonstrate their contribu-
tion to tumor metastatic activity. The linkage between
metabolism and tumor metastasis remains to be further
explored. The concept will also apply to other hypoxia/HIF-1α-regulated targets that appear not to be directly
regulating metastasis.
From this review, it appears that different categories of
targets can contribute to the metastatic process. Judging
from the various steps involved in tumor metastasis, it is
not surprising. However, it will need further investiga-
tion to figure out the exact mechanisms of how these
targets contribute to metastasis. In addition, the interact-
ing roles played by these targets to mediate metastasis
will also require an integrated approach to combine mo-
lecular biology and systems biology in order to put all
these players into a more comprehensive picture. Fur-
thermore, novel hypoxia/HIF-1α-regulated targets that
can mediate metastasis will need to be identified in
order to complete the full picture of tumor metastasis
induced by hypoxia/HIF-1α. Finally, elucidation of the
functions of these targets mediating metastasis will pro-
vide the possibility of using these targets as therapeutic
venues to improve the treatment of hypoxia-induced
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